A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease

被引:0
|
作者
Rugeri, Lucia [1 ]
Thomas, Will
Schirner, Kathrin
Heyder, Lisa
Auerswald, Guenter
机构
[1] Hop Cardiol, Unite Hemostase Clin, Hosp Civils Lyon, Lyon, France
关键词
blood products; factor VIII; systematic review; von Willebrand disease; von Willebrand factor; WFH; 2021; GUIDELINES; INHIBITOR DEVELOPMENT; VENOUS THROMBOSIS; CLINICAL-EFFICACY; MANAGEMENT; BIOSTATE(R); DIAGNOSIS; PHARMACOKINETICS; POPULATION; PREVENTION;
D O I
10.1055/a-2253-9701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background For the treatment of von Willebrand disease (VWD), von Willebrand factor (VWF) concentrates can be used in on-demand, long-term prophylaxis, and surgical prophylaxis regimens. Methods This systematic literature review was conducted to evaluate the efficacy, consumption, and safety of plasma-derived human coagulation FVIII/human VWF (pdVWF/FVIII; Voncento/Biostate) for the treatment of patients with any inherited VWD type. An electronic search was conducted in MEDLINE and Cochrane Library databases on VWD therapies. All retrieved publications were assessed against predefined inclusion/exclusion criteria following the Cochrane group recommendations. Associated pharmacovigilance data were collected across the same time period. Results Eleven publications from eight study cohorts were identified for data retrieval. All were from multicenter studies and included both pediatric and adult patients. Eight publications included evaluations of the efficacy of pdVWF/FVIII for on-demand treatment, eight included long-term prophylactic treatment, and eight included surgical prophylaxis. Treatment protocols and VWF administration methods differed between studies, as did safety evaluations. The clinical response was rated as excellent/good for on-demand treatment in 66 to 100% of nonsurgical bleeds, 89 to 100% in the treatment of breakthrough bleeds during long-term prophylaxis treatment, and hemostatic efficacy in surgical procedures was 75 to 100%. Pharmacovigilance data confirmed a low incidence of adverse events in treated patients. Conclusion This review provides a comprehensive summary of studies that evaluated the use of pdVWF/FVIII in VWD demonstrating the long-term effectiveness and safety of this pdVWF/FVIII across all ages, types of VWD, and treatment settings.
引用
收藏
页码:828 / 841
页数:14
相关论文
共 50 条
  • [41] Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery
    Windyga, Jerzy
    von Depka-Prondzinski, Mario
    THROMBOSIS AND HAEMOSTASIS, 2011, 105 (06) : 1072 - 1079
  • [42] Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease
    Roussi, J
    Turecek, PL
    André, P
    Bonneau, M
    Pignaud, G
    Sollier, CBD
    Schlokat, U
    Dorner, F
    Schwarz, HP
    Drouet, L
    BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 (04) : 361 - 372
  • [43] ADAMTS-13 content of plasma-derived factor VIII/von Willebrand factor concentrates
    Kingsland, Sarah
    Feldman, Peter
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : 667 - 668
  • [44] ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates
    Peyvandi, Flora
    Mannucci, Pier M.
    Valsecchi, Carla
    Pontiggia, Silvia
    Farina, Claudio
    Retzios, Anastassios D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (10) : 895 - 898
  • [45] Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates
    Clifton, James G.
    Huang, Feilei
    Kovac, Spomenka
    Yang, Xinli
    Hixson, Douglas C.
    Josic, Djuro
    ELECTROPHORESIS, 2009, 30 (20) : 3636 - 3646
  • [46] Managing von Willebrand disease with inhibitors during prophylaxis with a plasma derived von Willebrand factor/factor VIII concentrate-the WIL-31 study
    Khayat, C. D.
    Sidonio, R. F.
    Pavlova, A.
    HAEMOPHILIA, 2024, 30 : 131 - 131
  • [47] Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 Years
    Kittler, Sabine Friederike Karolin
    Miesbach, Wolfgang
    Bauhofer, Artur
    Becker, Thomas
    Schuettrumpf, Joerg
    Dubovy, Patrick
    Nemes, Laszlo
    Richter, Heinrich
    Koenigs, Christoph
    HAMOSTASEOLOGIE, 2019, 39 (04): : 360 - 367
  • [48] Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?
    Drillaud, Nicolas
    Ardillon, Laurent
    Ternisien, Catherine
    Valentin, Jean Baptiste
    Trossaert, Marc
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (02) : 128 - 129
  • [49] Dose linearity of von Willebrand factor factor VIII concentrate in elective surgery in von Willebrand disease patients.
    Mannucci, PM
    Kyrle, PA
    Schulman, S
    Haertel, S
    Lethagen, S
    BLOOD, 2003, 102 (11) : 312A - 312A
  • [50] An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)
    Lissitchkov, Toshko
    Klukowska, Anna
    Buevich, Evgeny
    Maltceva, Irina
    Auerswald, Guenter
    Stasyshyn, Oleksandra
    Seifert, Wilfried
    Rogosch, Tobias
    JOURNAL OF BLOOD MEDICINE, 2020, 11 : 345 - 356